Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
1.060
+0.005 (0.47%)
At close: Nov 4, 2024, 4:00 PM
1.000
-0.060 (-5.66%)
After-hours: Nov 4, 2024, 7:54 PM EST
Silo Pharma Revenue
Silo Pharma had revenue of $18.03K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $72.10K. In the year 2023, Silo Pharma had annual revenue of $72.10K.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
43.83
Revenue / Employee
$24,034
Employees
3
Market Cap
4.75M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
IM Cannabis | 36.45M |
Evoke Pharma | 7.53M |
Fresh2 Group | 2.34M |
Predictive Oncology | 1.75M |
Mangoceuticals | 866.79K |
SILO News
- 4 days ago - Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant - GlobeNewsWire
- 7 weeks ago - Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD - GlobeNewsWire
- 2 months ago - Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic - GlobeNewsWire
- 3 months ago - Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide - GlobeNewsWire
- 3 months ago - Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug - Benzinga